Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting.
Reddy PK, Patil S, Khobragade A, Balki A, Raj A, Kalikar M, Reddy R, Shinde R, Cr J, Mutha A, Boyilla N, Rajadhyaksha GC, Karnik N, Bhagat S, Pendse A, Dhage P, Wu W, Rangwala S, Barkate H. Reddy PK, et al. Among authors: rangwala s. Int J Gen Med. 2022 May 3;15:4551-4563. doi: 10.2147/IJGM.S349241. eCollection 2022. Int J Gen Med. 2022. PMID: 35535140 Free PMC article. Clinical Trial.
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, Kadam J, Wu W, Caracta CF, Tandon M. Udwadia ZF, et al. Among authors: rangwala s. Int J Infect Dis. 2021 Feb;103:62-71. doi: 10.1016/j.ijid.2020.11.142. Epub 2020 Nov 16. Int J Infect Dis. 2021. PMID: 33212256 Free PMC article. Clinical Trial.
Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
Udwadia ZF, Barkate H, Patil S, Rangwala S, Wu W, Caracta CF, Tandon M. Udwadia ZF, et al. Among authors: rangwala s. Int J Infect Dis. 2021 Apr;105:686-687. doi: 10.1016/j.ijid.2021.02.028. Epub 2021 Feb 15. Int J Infect Dis. 2021. PMID: 33601032 Free PMC article. No abstract available.
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial.
Salvi S, Balki A, Krishnamurthy S, Panchal S, Patil S, Kodgule R, Khandagale H, Pendse A, Wu W, Rangwala S, Tandon M, Barkate H. Salvi S, et al. Among authors: rangwala s. ERJ Open Res. 2021 Jul 26;7(3):00255-2021. doi: 10.1183/23120541.00255-2021. eCollection 2021 Jul. ERJ Open Res. 2021. PMID: 34322547 Free PMC article.
Syndrome d’hyperstimulation ovarienne.
Rosenberg H, Rangwala S, Magee B. Rosenberg H, et al. Among authors: rangwala s. CMAJ. 2024 Nov 24;196(40):E1355-E1356. doi: 10.1503/cmaj.240213-f. CMAJ. 2024. PMID: 39586602 Free PMC article. French. No abstract available.
Ovarian hyperstimulation syndrome.
Rosenberg H, Rangwala S, Magee B. Rosenberg H, et al. Among authors: rangwala s. CMAJ. 2024 Sep 9;196(29):E1012. doi: 10.1503/cmaj.240213. CMAJ. 2024. PMID: 39251242 Free PMC article. No abstract available.
132 results